bioMerieux (OTCMKTS:BMXMF) Shares Gap Down – Here’s What Happened

Shares of bioMerieux (OTCMKTS:BMXMF) gapped down before the market opened on Wednesday . The stock had previously closed at $86.88, but opened at $83.27. bioMerieux shares last traded at $83.27, with a volume of 302 shares.

Wall Street Analyst Weigh In

BMXMF has been the subject of a number of recent analyst reports. Zacks Research downgraded bioMerieux from a “hold” rating to a “strong sell” rating in a report on Friday, July 31st. Morgan Stanley reaffirmed an “underweight” rating on shares of bioMerieux in a research note on Friday. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of bioMerieux in a report on Wednesday, June 17th. UBS Group downgraded shares of bioMerieux from a “buy” rating to a “neutral” rating in a report on Monday, June 1st. Finally, Piper Sandler assumed coverage on shares of bioMerieux in a research report on Thursday, June 11th. They set a “neutral” rating on the stock. Four investment analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, bioMerieux currently has an average rating of “Reduce”.

bioMerieux Trading Down 4.2%

The company has a current ratio of 2.39, a quick ratio of 1.48 and a debt-to-equity ratio of 0.08. The stock has a 50-day simple moving average of $82.56 and a 200 day simple moving average of $90.38.

bioMerieux Company Profile

bioMérieux (OTCMKTS:BMXMF) is a France-based company specializing in in vitro diagnostics. It develops, manufactures and markets diagnostic systems used to detect infectious diseases, support antimicrobial treatment decisions and improve patient care in clinical settings.

The company’s product portfolio includes molecular biology tests, microbiology systems, immunoassays and syndromic testing solutions. Its clinical diagnostic products are used by hospitals, laboratories and other healthcare providers, while its industrial applications serve the food, pharmaceutical and cosmetic industries through solutions for detecting microorganisms and monitoring contamination.

Established in 1963, bioMérieux traces its roots to the Mérieux family’s longstanding involvement in medical research and diagnostics in France.